Equity
ANALYST VIEW - Jefferies downgrades Hungary's Richter over Esmya woes
Richter announced late on Monday that a probe of Esmya is expected to cause impairment loss of 42 billion forints, and as a result of the temporary suspension of Esmya sales, the group’s 2017 results will also be impacted negatively.James Vane-Tempest, a London-based equity analyst at Jefferies, has on Tuesday
He believes “this is prudent" in light of PRAC recommendations and HUF 42bn write-down, and he now takes a bearish view of the upcoming US PDUFA decision.
Vane-Tempest “also reflects a tougher base due to pricing pressure and a sluggish OC market in EU, directly impacting profitability." He sees scope for disappointment with no margin guidance; believing cons is too high, hence the downgrade to ‘Hold’.
With the PRAC issuing temporary recommendations the analyst expects Esmya sales to fall by 60% in '18.
“We now believe a US approval is unlikely and further data analysis will be required despite no direct connection to the drug and believe it is prudent to remove it from our model entirely."
The analyst added that a positive outcome in EU & US increases 2020E EPS by 22%.
The recognition of a HUF 42 bn impairment loss in Richter’s 2017 financials from intangibles linked to Esmya (carrying amount at Dec '16 HUF 71bn) corresponds to cc. HUF 226/share, the analyst noted.
“While we present our financials excl. the impact, we look for clarity on the P&L impact. As sensitivity, we expect the reduced amortisation would benefit EBIT by c.2.5%. We believe that further write-downs are possible if the EMA outcome is unfavourable."
Jefferies anticipates lower margins with the Esmya setback, estimating that Richter’s 56.8% GM in 2017 was c.57.3% excluding a one-off HUF 2.3 bn reclassification of other expenses to COGS.
This year, Jefferies estimates 56.5% as despite Esmya impact, it expects higher Vraylar US royalties to help offset decline as well as the launch in EU by REC, though it projects higher u/l costs. Vane-Tempest forecasts EBIT margins to decline as he expects operational deleverage despite marketing savings; hence his 14.5% forecast vs. 15.5% in '17.
“There is a sizeable sales force associated with Esmya, though some could be redeployed. The base business also appears stagnant with the number of women taking OCs in EU declining."
lowered his earnings per share (EPS) estimate for Richter by 20-25%, slashed his target price to HUF 5,695 from HUF 8,355 previously and downgraded the stock to ‘Hold’ from ‘Buy’.
Additionally, he has removed Esmya from his model.He believes “this is prudent" in light of PRAC recommendations and HUF 42bn write-down, and he now takes a bearish view of the upcoming US PDUFA decision.
Vane-Tempest “also reflects a tougher base due to pricing pressure and a sluggish OC market in EU, directly impacting profitability." He sees scope for disappointment with no margin guidance; believing cons is too high, hence the downgrade to ‘Hold’.
With the PRAC issuing temporary recommendations the analyst expects Esmya sales to fall by 60% in '18.
“We now believe a US approval is unlikely and further data analysis will be required despite no direct connection to the drug and believe it is prudent to remove it from our model entirely."
The analyst added that a positive outcome in EU & US increases 2020E EPS by 22%.
The recognition of a HUF 42 bn impairment loss in Richter’s 2017 financials from intangibles linked to Esmya (carrying amount at Dec '16 HUF 71bn) corresponds to cc. HUF 226/share, the analyst noted.
“While we present our financials excl. the impact, we look for clarity on the P&L impact. As sensitivity, we expect the reduced amortisation would benefit EBIT by c.2.5%. We believe that further write-downs are possible if the EMA outcome is unfavourable."
Jefferies anticipates lower margins with the Esmya setback, estimating that Richter’s 56.8% GM in 2017 was c.57.3% excluding a one-off HUF 2.3 bn reclassification of other expenses to COGS.
This year, Jefferies estimates 56.5% as despite Esmya impact, it expects higher Vraylar US royalties to help offset decline as well as the launch in EU by REC, though it projects higher u/l costs. Vane-Tempest forecasts EBIT margins to decline as he expects operational deleverage despite marketing savings; hence his 14.5% forecast vs. 15.5% in '17.
“There is a sizeable sales force associated with Esmya, though some could be redeployed. The base business also appears stagnant with the number of women taking OCs in EU declining."
Key estimate changes:
- 2018 revenues: HUF 440.7 bn (vs. HUF 462.3 bn)
- 2019 revenues: HUF 458.5 bn (HUF 496.5 bn)
- 2020 revenues: HUF 485.8 (HUF 519.6 bn)
- 2018 EPS: HUF 373 (HUF 499)
- 2019 EPS: HUF 382 (HUF 555)
- 2020 EPS: HUF 421 (HUF 605)
- 2018 EBITDA: HUF 97.6 bn (HUF 119.3 bn)
- 2019 EBITDA: HUF 99 bn (HUF 129.4 bn)
- 2020 EBITDA: HUF 106.3 bn (HUF 138.5 bn)











